---
document_datetime: 2024-09-09 12:14:36
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nyxthracis-previously-obiltoxaximab-sfl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nyxthracis-previously-obiltoxaximab-sfl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9923559
conversion_datetime: 2025-12-30 01:13:02.297902
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| product   |
|-----------|

Medicinal product no longer authorised

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonthsof the opinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(Eu)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                   |    | longer authorised   |
|-------------------|----|---------------------|
| Medicinal product | no |                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->